Log in

NASDAQ:APEN - Apollo Endosurgery Stock Price, Forecast & News

$2.72
+0.16 (+6.25 %)
(As of 02/27/2020 07:12 AM ET)
Today's Range
$2.65
Now: $2.72
$2.72
50-Day Range
$2.56
MA: $2.93
$3.20
52-Week Range
$2.50
Now: $2.72
$4.08
Volume10,349 shs
Average Volume10,985 shs
Market Capitalization$56.96 million
P/E RatioN/A
Dividend YieldN/A
Beta0.8
Apollo Endosurgery, Inc, a medical technology company, focuses on the design, development, and commercialization of medical devices. Its products include OverStitch and OverStitch Sx Endoscopic Suturing System that enables advanced endoscopic procedures by allowing physicians to place full thickness sutures and secure the approximation of tissue through a flexible endoscope; Orbera365 Managed Weight Loss System; and the BIB for the treatment of overweight and obese adults. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:APEN
CUSIPN/A
Phone512-279-5100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$60.85 million
Book Value$1.32 per share

Profitability

Net Income$-45,790,000.00

Miscellaneous

Employees215
Market Cap$56.96 million
Next Earnings Date3/16/2020 (Estimated)
OptionableNot Optionable

Receive APEN News and Ratings via Email

Sign-up to receive the latest news and ratings for APEN and its competitors with MarketBeat's FREE daily newsletter.


Apollo Endosurgery (NASDAQ:APEN) Frequently Asked Questions

What is Apollo Endosurgery's stock symbol?

Apollo Endosurgery trades on the NASDAQ under the ticker symbol "APEN."

How were Apollo Endosurgery's earnings last quarter?

Apollo Endosurgery Inc (NASDAQ:APEN) issued its quarterly earnings results on Wednesday, October, 30th. The biotechnology company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.42) by $0.02. The biotechnology company had revenue of $11.26 million for the quarter, compared to analysts' expectations of $13.37 million. Apollo Endosurgery had a negative net margin of 71.59% and a negative return on equity of 176.86%. View Apollo Endosurgery's Earnings History.

When is Apollo Endosurgery's next earnings date?

Apollo Endosurgery is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Apollo Endosurgery.

Has Apollo Endosurgery been receiving favorable news coverage?

Media stories about APEN stock have been trending positive recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Apollo Endosurgery earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the immediate future. View News Stories for Apollo Endosurgery.

Are investors shorting Apollo Endosurgery?

Apollo Endosurgery saw a decline in short interest in February. As of February 14th, there was short interest totalling 145,200 shares, a decline of 11.9% from the January 30th total of 164,900 shares. Based on an average trading volume of 13,300 shares, the short-interest ratio is presently 10.9 days. Approximately 1.2% of the shares of the company are sold short. View Apollo Endosurgery's Current Options Chain.

Who are some of Apollo Endosurgery's key competitors?

What other stocks do shareholders of Apollo Endosurgery own?

Who are Apollo Endosurgery's key executives?

Apollo Endosurgery's management team includes the folowing people:
  • Mr. Todd Newton, CEO & Director (Age 56)
  • Dr. Sergey Kantsevoy M.D., Co-Founder and Innovation Partner
  • Mr. Anthony Kalloo M.D., Co-Founder and Innovation Partner
  • Dr. Robert Hawes M.D., Co-Founder and Innovation Partner
  • Dr. Peter Benjamin Cotton M.D., Co-Founder and Innovation Partner

Who are Apollo Endosurgery's major shareholders?

Apollo Endosurgery's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Gagnon Securities LLC (4.77%), Renaissance Technologies LLC (0.41%), Russell Investments Group Ltd. (0.36%) and University of Texas Texas AM Investment Managment Co. (0.07%). Company insiders that own Apollo Endosurgery stock include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Institutional Ownership Trends for Apollo Endosurgery.

Which institutional investors are selling Apollo Endosurgery stock?

APEN stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd.. View Insider Buying and Selling for Apollo Endosurgery.

Which institutional investors are buying Apollo Endosurgery stock?

APEN stock was purchased by a variety of institutional investors in the last quarter, including Gagnon Securities LLC, University of Texas Texas AM Investment Managment Co. and Renaissance Technologies LLC. Company insiders that have bought Apollo Endosurgery stock in the last two years include Matthew S Crawford, Stefanie L Cavanaugh, Stonepine Capital, LP and Todd Newton. View Insider Buying and Selling for Apollo Endosurgery.

How do I buy shares of Apollo Endosurgery?

Shares of APEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Apollo Endosurgery's stock price today?

One share of APEN stock can currently be purchased for approximately $2.72.

How big of a company is Apollo Endosurgery?

Apollo Endosurgery has a market capitalization of $56.96 million and generates $60.85 million in revenue each year. The biotechnology company earns $-45,790,000.00 in net income (profit) each year or ($1.92) on an earnings per share basis. Apollo Endosurgery employs 215 workers across the globe.View Additional Information About Apollo Endosurgery.

What is Apollo Endosurgery's official website?

The official website for Apollo Endosurgery is http://www.apolloendo.com/.

How can I contact Apollo Endosurgery?

Apollo Endosurgery's mailing address is 1120 SOUTH CAPITAL OF TX HWY BUILDING 1 SUITE 300, AUSTIN TX, 78746. The biotechnology company can be reached via phone at 512-279-5100 or via email at [email protected]


MarketBeat Community Rating for Apollo Endosurgery (NASDAQ APEN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  179 (Vote Underperform)
Total Votes:  387
MarketBeat's community ratings are surveys of what our community members think about Apollo Endosurgery and other stocks. Vote "Outperform" if you believe APEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel